Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
Lymphoma
OTHER: Non-Interventional
Treatment-Related Mortality (TRM), Treatment-Related Mortality at 6 months after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab, At 6 months after an allogeneic HCT
Incidence of disease progression, Measured by clinical assessment, Up to 2 years|Incidence of acute Graft Versus Host Disease (GVHD), Either Grade II-IV or Grade III-IV acute GVHD. Measured by clinical assessment, Up to 2 years|Incidence of chronic Graft Versus Host Disease (GVHD), Measured by clinical assessment, Up to 2 years|Incidence of post-transplant sinusoidal obstruction syndrome (SOS), Measured by clinical assessment, Up to 2 years|Incidence of post-transplant interstitial pneumonitis (IPN), Measured by clinical assessment, Up to 2 years|Incidence of post-transplant renal toxicity requiring dialysis, Measured by clinical assessment, Up to 2 years|Overall Survival (OS), OS is measured from the date of allogeneic transplant to death., Up to 2 years|Progression-Free Survival (PFS), PFS is measured from the date of allogeneic transplant to the date of disease progression or death., Up to 2 years|TRM at 100 days, Treatment-Related Mortality at 100 days after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab, At 100 days after an allogeneic HCT|TRM at 1 year, Treatment-Related Mortality at 1 year after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab, At 1 year after an allogeneic HCT|TRM at 2 years, Treatment-Related Mortality at 2 years after an allogeneic Hemaetopoietic Cell Transplantation (HCT) among patients with cHL who were previously treated with nivolumab, At 2 years after an allogeneic HCT
This study will include a retrospective and prospective observational database analysis.